Zimbabwe has declined a major American health deal valued at $367m (£272m) over five years over the United States' insistence on confidential biological samples.
This move was revealed following a official document dated December was disclosed, revealing that President Emmerson Mnangagwa believed the agreement was "unbalanced".
An official spokesman has since explained that the United States was seeking biological samples for research and commercial gain while was unwilling to share the benefits from future medical innovations.
"We must now begin the challenging and unfortunate task of winding down our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the US had furnished more than $1.9bn for health programmes to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has called for more negotiations to reach a deal suitable to both sides so the country's critical HIV treatment initiative can continue.
Broader Implications
This rejection comes after a comparable case in Kenya, where a high court halted a related health funding agreement after legal challenges were filed about the security of citizens' health data.
After resuming office last year, US President Donald Trump has slashed overseas assistance and shut down the key foreign aid agency.
USAID had overseen aid for the American government, but Trump argued its expenditure was "wasteful" and his administration was pursuing government-to-government agreements to enhance transparency and responsibility.
According to reports, Sixteen nations in Africa have so far signed similar health pacts, representing over $18.3bn in new funding.
Specifics of the Declined Agreement
The money for Zimbabwe would have funded "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"It is our view this collaboration could have provided extraordinary advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children presently receiving HIV treatment via American-funded programmes," the Ambassador added.
However, official spokesman Nick Mangwana maintained the proposed deal was "unfair".
"Zimbabwe was being asked to share its genetic material and health information indefinitely, without any corresponding promise of access to any medical innovations – like new medicines or tests – that might be developed from that shared data," he stated.
"In essence, our nation would provide the basic resources for scientific discovery with no certainty that the end products would be available to our population if a future pandemic arise."
Sovereignty and International Frameworks
He also noted that the American exit from the World Health Organization (WHO) and its push of one-on-one health agreements were upending frameworks previously set up through the international health agency.
The spokesperson cited its Pandemic Benefit-Sharing scheme designed to manage potential global health emergencies.
"This mechanism is intended to guarantee that when a country provides its samples, the resulting advantages – such as medicines and cures – are distributed fairly, not monopolised exclusively by those with the resources to develop them."
The government's concerns over the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We are open to further dialogue with our US partners on how subsequent co-operation might be designed in a manner that honours the sovereignty and interests of both nations."
Health Experts Reaction
Medical experts expressed it understood the official position, but recommended that talks need to persist since a large portion of the country's HIV programmes depended on foreign aid.
"If technical issues arise, including those involving data governance or agreement terms, these can often be resolved via technical clarification and mutually agreed protections," the group commented.
The situation emphasises the complex debate between accepting crucial international aid and safeguarding local interests in an increasingly data-driven world.